Clavis, Skyline Diagnostics deal

Skyline will investigate gene expression biomarkers to screen for patients with acute myelogenous leukemia (AML) that may benefit from Clavis' elacytarabine. The lipid Vector Technology (LVT) derivative of cytarabine (Ara-C) is in Phase III testing to treat relapsed or refractory AML. Elacytarabine has Fast Track and Orphan Drug designations in the U.S., and Orphan designation in the EU to treat AML. Details were not disclosed. ...